Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Next Previous
Trial Profile

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Expanded access
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 04 Dec 2018 Results (Dec 29, 2017) consolidated findings from the Expanded Treatment Protocol study at week 96 data cut off, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 Algeria, Argentina, Brazil, Colombia, Croatia, Estonia, Hungary, India, Indonesia, Israel, Italy, Jordan, Lebanon, Morocco, Netherlands, Poland, Romania, Saudi Arabia, Slovakia, Slovenia, South Africa, South Korea, Spain, Taiwan, Tunisia, Venezuela were the planned locations as per European Clinical Trials Database record.
    • 21 Mar 2018 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top